Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic
Matthew Feldman,* Sarah Marmol,* Jason Margolesky Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA*These authors contributed equally to this workCorrespondence: Jason Margolesky, Department of Neurology, University of Miami Miller School...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2022-12-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/updated-perspectives-on-the-management-of-drug-induced-parkinsonism-di-peer-reviewed-fulltext-article-TCRM |
| _version_ | 1811288862117330944 |
|---|---|
| author | Feldman M Marmol S Margolesky J |
| author_facet | Feldman M Marmol S Margolesky J |
| author_sort | Feldman M |
| collection | DOAJ |
| description | Matthew Feldman,* Sarah Marmol,* Jason Margolesky Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA*These authors contributed equally to this workCorrespondence: Jason Margolesky, Department of Neurology, University of Miami Miller School of Medicine, 1150 NW 14th St, Miami, FL, 33136, USA, Email jhmargolesky@med.miami.eduAbstract: Parkinsonism refers to the clinical combination of bradykinesia, rigidity, tremor, and postural instability. Parkinsonism is often neurodegenerative, but it can be secondary or iatrogenic, as in drug-induced parkinsonism (DIP), which is the topic of this review. We review the pathophysiology of DIP, differentiate DIP and idiopathic Parkinson’s disease (PD), list culprit medications in the development of DIP, discuss the diagnosis of DIP as well as the motor and nonmotor signs and symptoms that can help with differentiation of DIP and PD, and detail the management of DIP.Keywords: drug-induced parkinsonism, neuroleptic-induced parkinsonism, Parkinson’s disease |
| first_indexed | 2024-04-13T03:44:44Z |
| format | Article |
| id | doaj.art-896cee87f5774c4994f0f97ac9143aa4 |
| institution | Directory Open Access Journal |
| issn | 1178-203X |
| language | English |
| last_indexed | 2024-04-13T03:44:44Z |
| publishDate | 2022-12-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Therapeutics and Clinical Risk Management |
| spelling | doaj.art-896cee87f5774c4994f0f97ac9143aa42022-12-22T03:04:03ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2022-12-01Volume 181129114280488Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the ClinicFeldman MMarmol SMargolesky JMatthew Feldman,* Sarah Marmol,* Jason Margolesky Department of Neurology, University of Miami Miller School of Medicine, Miami, FL, USA*These authors contributed equally to this workCorrespondence: Jason Margolesky, Department of Neurology, University of Miami Miller School of Medicine, 1150 NW 14th St, Miami, FL, 33136, USA, Email jhmargolesky@med.miami.eduAbstract: Parkinsonism refers to the clinical combination of bradykinesia, rigidity, tremor, and postural instability. Parkinsonism is often neurodegenerative, but it can be secondary or iatrogenic, as in drug-induced parkinsonism (DIP), which is the topic of this review. We review the pathophysiology of DIP, differentiate DIP and idiopathic Parkinson’s disease (PD), list culprit medications in the development of DIP, discuss the diagnosis of DIP as well as the motor and nonmotor signs and symptoms that can help with differentiation of DIP and PD, and detail the management of DIP.Keywords: drug-induced parkinsonism, neuroleptic-induced parkinsonism, Parkinson’s diseasehttps://www.dovepress.com/updated-perspectives-on-the-management-of-drug-induced-parkinsonism-di-peer-reviewed-fulltext-article-TCRMdrug-induced parkinsonismneuroleptic-induced parkinsonismparkinson’s disease |
| spellingShingle | Feldman M Marmol S Margolesky J Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic Therapeutics and Clinical Risk Management drug-induced parkinsonism neuroleptic-induced parkinsonism parkinson’s disease |
| title | Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic |
| title_full | Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic |
| title_fullStr | Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic |
| title_full_unstemmed | Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic |
| title_short | Updated Perspectives on the Management of Drug-Induced Parkinsonism (DIP): Insights from the Clinic |
| title_sort | updated perspectives on the management of drug induced parkinsonism dip insights from the clinic |
| topic | drug-induced parkinsonism neuroleptic-induced parkinsonism parkinson’s disease |
| url | https://www.dovepress.com/updated-perspectives-on-the-management-of-drug-induced-parkinsonism-di-peer-reviewed-fulltext-article-TCRM |
| work_keys_str_mv | AT feldmanm updatedperspectivesonthemanagementofdruginducedparkinsonismdipinsightsfromtheclinic AT marmols updatedperspectivesonthemanagementofdruginducedparkinsonismdipinsightsfromtheclinic AT margoleskyj updatedperspectivesonthemanagementofdruginducedparkinsonismdipinsightsfromtheclinic |